1620675-50-4Relevant articles and documents
Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo[1,5-a]pyrazine core featuring 3-position bicyclic ring substitutes
Alhassan, Abdul-Basit,Anand, Rajan,Babu Boga, Sobhana,Bennett, Chad,Brandish, Philip E.,Cai, Jiaqiang,Duffy, Joseph L.,Fischmann, Thierry O.,Gao, Xiaolei,Gao, Ying-Duo,Garlisi, Charles G.,Guiadeen, Deodial,Hicks, Alexandra,Kelly, Joseph,Kim, Ronald,Knemeyer, Ian,Kozlowski, Joseph A.,Krikorian, Arto,Leccese, Erica,Liu, Jian,Liu, Shilan,Maloney, Kevin M.,Mansueto, My,Presland, Jeremy,Selyutin, Oleg,Stivers, Peter,Tyagarajan, Sriram,Wang, James,Wu, Hao,Xu, Jiayi,Xu, Zangwei,Yang, Chundao,Yu, Wensheng,Yu, Younong,Zhang-Hoover, Jie
, (2020/07/27)
Bruton's tyrosine kinase (BTK) is a Tec family kinase with a well-defined role in the B cell receptor (BCR) pathway. It has become an attractive kinase target for selective B cell inhibition, and for the treatment of B cell related diseases. Many BTK inhibitors have been discovered for the treatment of cancer and rheumatoid arthritis, including a series of BTK inhibitors based on 8-amino-imidazo[1,5-a]pyrazine we recently reported. The X-ray crystal structures of BTK with inhibitors were also published, which provided great help for the SAR design. Here we report our SAR work introducing ring constraints for the 3-position piperidine amides on the BTK inhibitors based on 8-amino-imidazo[1,5-a]pyrazine. This modification improved the potency in BTK inhibitions, as well as the PK profile and the off-target selectivity. The dose-dependent efficacy of two BTK inhibitors was observed in the rat collagen induced arthritis (CIA) model.
BTK INHIBITORS
-
, (2016/07/27)
Provided are Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions comprising these compounds and their use in therapy. In particular, provided is the use of Btk inhibitor compounds of Formula I in the treatment of Btk mediated disorders.
BTK INHIBITORS
-
, (2014/08/07)
The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.
